The global Radioligand Therapy Drugs for Cancer market size is predicted to grow from US$ 3203 million in 2025 to US$ 5447 million in 2032; it is expected to grow at a CAGR of 8.0% from 2026 to 2032.

In 2025, global Radioligand Therapy Drugs for Cancer reached approximately 76.86 K Units, with an average global market price of around 42598 USD per Unit.

Radioligand Therapy (RLT) drugs are targeted radiopharmaceutical cancer medicines that pair a tumor-seeking ?ligand? (targeting molecule) with a therapeutic radioactive isotope (radionuclide). After intravenous administration, the ligand binds to a specific target on (or in) cancer cells, and the radionuclide delivers cell-killing radiation locally, aiming to limit exposure to surrounding healthy tissue.

Radioligand therapy (RLT) drugs combine the precision of targeted medicine with the cell-killing power of radiation, delivering a therapeutic payload directly to tumors based on a molecular marker rather than just anatomy, which helps address several long-standing pain points in oncology: limited efficacy after multiple lines of treatment, high systemic toxicity from broadly acting drugs, and the need for better patient selection to avoid costly trial-and-error care. By pairing a targeting ligand with a therapeutic radioisotope, RLT can concentrate dose where disease is active?including small or disseminated lesions?while often remaining compatible with existing imaging workflows and multidisciplinary cancer care, making outcomes more predictable and enabling clearer treatment sequencing. Industry momentum is being driven by a convergence of factors: rapid growth in biomarker-guided oncology, rising unmet need in hard-to-treat metastatic disease, increasing confidence from real-world clinical adoption, and meaningful investment in isotope supply, manufacturing capacity, and specialized treatment infrastructure that reduces earlier bottlenecks. Looking ahead, the market potential is reinforced by a deepening pipeline across multiple tumor types and targets, next-generation isotopes and chemistries that may improve tumor penetration and durability, and expanding global capacity that can progressively normalize availability; as these elements mature, RLT is positioned to evolve from a niche option into a more routine modality that complements?and in some settings competes with?established systemic therapies, shaping a long runway for growth without relying on hype.

Radioligand Therapy Drugs for Cancer upstream raw materials mainly include therapeutic radionuclides, targeted ligands, and excipients. Typical suppliers include ITM, Curium, SHINE Technologies, and NRG. Downstream applications primarily involve the treatment of cancers such as prostate cancer, liver cancer, breast cancer, and lung cancer.

The production capacity of a single Radioligand Therapy Drugs for Cancer production line is affected by the supply of radionuclides, synthesis efficiency, equipment configuration, and quality control standards. Significant differences exist between different drugs and production lines. Radioligand Therapy Drugs for Cancer gross profit margin ranges from 70% to 80%.

United States market for Radioligand Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Radioligand Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Radioligand Therapy Drugs for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Radioligand Therapy Drugs for Cancer players cover Novartis, Bayer, Progenics (Lantheus), Acrotech Biopharma Inc, BMS, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

Infinity Market Research newest research report, the ?Radioligand Therapy Drugs for Cancer Industry Forecast? looks at past sales and reviews total world Radioligand Therapy Drugs for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Radioligand Therapy Drugs for Cancer sales for 2026 through 2032. With Radioligand Therapy Drugs for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radioligand Therapy Drugs for Cancer industry.

This Insight Report provides a comprehensive analysis of the global Radioligand Therapy Drugs for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radioligand Therapy Drugs for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Radioligand Therapy Drugs for Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radioligand Therapy Drugs for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radioligand Therapy Drugs for Cancer.

This report presents a comprehensive overview, market shares, and growth opportunities of Radioligand Therapy Drugs for Cancer market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Lutetium 177
    Radium 223
    Acetium 225
    Others
    Segmentation by Targeted Ligands:
    by Peptides
    Small Molecules
    Antibodies
    Others
    Segmentation by Radionuclides:
    ?-emitters
    -emitters
    Others

Segmentation by Application:

    Prostate Cancer
    Liver Cancer
    Breast Cancer
    Lung Cancer
    Others

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Novartis
    Bayer
    Progenics (Lantheus)
    Acrotech Biopharma Inc
    BMS
    AstraZeneca
    Eli Lilly
    Convergent Therapeutics
    Grand Pharmaceutical
    Bivision Pharmaceuticals
    Jiangsu Hengrui

Key Questions Addressed in this Report

What is the 10-year outlook for the global Radioligand Therapy Drugs for Cancer market?
What factors are driving Radioligand Therapy Drugs for Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Radioligand Therapy Drugs for Cancer market opportunities vary by end market size?
How does Radioligand Therapy Drugs for Cancer break out by Type, by Application?